(NASDAQ: TLSI) Trisalus Life Sciences's forecast annual revenue growth rate of 44.4% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.2%.
Trisalus Life Sciences's revenue in 2026 is $40,207,000.On average, 9 Wall Street analysts forecast TLSI's revenue for 2026 to be $3,201,862,942, with the lowest TLSI revenue forecast at $2,937,901,487, and the highest TLSI revenue forecast at $3,530,728,037. On average, 6 Wall Street analysts forecast TLSI's revenue for 2027 to be $4,538,558,154, with the lowest TLSI revenue forecast at $4,045,760,155, and the highest TLSI revenue forecast at $4,847,337,596.
In 2028, TLSI is forecast to generate $6,093,647,370 in revenue, with the lowest revenue forecast at $5,527,551,726 and the highest revenue forecast at $6,479,371,850.